Search results for "droni."

showing 10 items of 596 documents

Aqua Mater: On the Meaning of the Theonym Betatun

2021

La aparición en el entorno del santuario tardoibérico de Las Atalayuelas (Fuerte del Rey – Torredelcampo, Jaén) de una inscripción en la que se documenta el teónimo ibérico Betatun abre nuevas perspectivas en el estudio de la religión ibérica. Con el presente artículo intentamos demostrar que en el nombre de la divinidad está implícito un elemento común que lo relacionaría con una serie de topónimos e hidrónimos, tanto antiguos como modernos, y que no es otro que el agua. The finding of an inscription containing the Iberian theonym Betatun in the surrounding area of the Late Iberian sanctuary in Las Atalayuelas site (Fuerte del Rey – Torredelcampo, Jaén) opens up new perspectives for the st…

010506 paleontologyArcheologyHistory05 social sciencessincretismos050109 social psychologyToponímiaHistòria antigaToponymysantuarios ibéricos01 natural sciencesIberian ShrinesSyncretismsdioses ibéricosHydronymy0501 psychology and cognitive scienceshidronimiaClassicsIberian Godstoponimia0105 earth and related environmental sciences
researchProduct

Extensive osteonecrosis of the maxilla caused by bisphosphonates: Report of a rare case

2019

Bisphosphonates are drugs indicated for the treatment of bone metabolic diseases or malignant hypercalcemia. They are generally well-tolerated drugs, however, recent reports have described osteonecrosis of the jaw bones as a potentially serious complication related to the long-term use of these drugs. We report a case of severe osteonecrosis in a 52-years-old white woman that was taking bisphosphonates (zoledronic acid and alendronate) for the management of osteoporosis. Following a long exposure to these drugs and after being subjected to multiples exodontias, developed bisphosphonate-related osteonecrosis of the jaw compromising the whole maxilla and that extended toward the base of skull…

0301 basic medicine030103 biophysicsmedicine.medical_specialtymedicine.medical_treatmentOsteoporosisCase Report03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineUltraviolet lightGeneral DentistryBase of skullbusiness.industryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgerystomatognathic diseasesZoledronic acidMaxillaUNESCO::CIENCIAS MÉDICASOral SurgeryOsteonecrosis of the jawComplicationbusiness030217 neurology & neurosurgerymedicine.drugJournal of Clinical and Experimental Dentistry
researchProduct

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?

2016

// Daniele Fanale 1, * , Valeria Amodeo 1, * , Viviana Bazan 1, * , Lavinia Insalaco 1 , Lorena Incorvaia 1 , Nadia Barraco 1 , Marta Castiglia 1 , Sergio Rizzo 1 , Daniele Santini 2 , Antonio Giordano 3 , Sergio Castorina 4, 5, # , Antonio Russo 1, # 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 University Campus Bio-Medico, Department of Medical Oncology, Rome, Italy 3 Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, PA, USA 4 Fondazione Mediterranea “G.B. Morgagni”, Catania, Italy 5 Department of Biomedic…

0301 basic medicineAntineoplastic AgentsBreast NeoplasmsBioinformatics03 medical and health sciencesBreast cancer0302 clinical medicineBreast cancermicroRNAmedicineHumansZoledronic acidPI3K/AKT/mTOR pathwaybone metastasisBone Density Conservation AgentsDiphosphonatesMicroarray analysibusiness.industryGene Expression ProfilingImidazolesBone metastasisMicroRNA Expression Profilemedicine.diseaseActin cytoskeletonMolecular medicineBone metastasis; Breast cancer; Microarray analysis; miRNA expression profile; Zoledronic acid; Oncology030104 developmental biologyZoledronic acidOncologyBone metastasi030220 oncology & carcinogenesisMCF-7 CellsCancer researchmiRNA expression profilemicroarray analysisTranscriptomebusinessResearch Papermedicine.drug
researchProduct

Amorphous, Smart, and Bioinspired Polyphosphate Nano/Microparticles: A Biomaterial for Regeneration and Repair of Osteo-Articular Impairments In-Situ

2018

Using femur explants from mice as an in vitro model, we investigated the effect of the physiological polymer, inorganic polyphosphate (polyP), on differentiation of the cells of the bone marrow in their natural microenvironment into the osteogenic and chondrogenic lineages. In the form of amorphous Ca-polyP nano/microparticles, polyP retains its function to act as both an intra- and extracellular metabolic fuel and a stimulus eliciting morphogenetic signals. The method for synthesis of the nano/microparticles with the polyanionic polyP also allowed the fabrication of hybrid particles with the bisphosphonate zoledronic acid, a drug used in therapy of bone metastases in cancer patients. The r…

0301 basic medicineBone Regenerationlong bone defects; bone marrow cells; inorganic polyphosphate; microparticles; bisphosphonates; <i>Runx2</i>; <i>Sox9</i>; cathepsin-K; tumor metastases; human mesenchymal stem cellsmedicine.medical_treatmentBiocompatible MaterialsCore Binding Factor Alpha 1 SubunitZoledronic Acidlcsh:ChemistryMiceRunx2OsteogenesisPolyphosphatesFemurlcsh:QH301-705.5tumor metastasesSpectroscopymicroparticlescathepsin-KDiphosphonatesTissue ScaffoldsChemistryImidazolesBiomaterialSOX9 Transcription FactorGeneral MedicineUp-RegulationComputer Science ApplicationsCell biologyRUNX2medicine.anatomical_structureinorganic polyphosphateChondrogenesisSox9medicine.drugArticleCatalysisChondrocyteInorganic Chemistryhuman mesenchymal stem cells03 medical and health sciencesOsteoclastmedicineAnimalsHumansPhysical and Theoretical Chemistrybone marrow cellsbisphosphonatesMolecular BiologyOrganic ChemistryMesenchymal stem cellMesenchymal Stem CellsBisphosphonateRatslong bone defects030104 developmental biologyZoledronic acidlcsh:Biology (General)lcsh:QD1-999Gene Expression RegulationNanoparticlesBone marrowInternational Journal of Molecular Sciences
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Non-Radiation Based Early Pain Relief Treatment Options for Patients With Non-Small Cell Lung Cancer and Cancer Induced Bone Pain: A Systematic Review

2020

Introduction: Cancer induced bone pain (CIBP) is frequent in patients with non-small cell lung cancer (NSCLC). Radiation therapy continues to be the gold standard for treatment of painful bone metastases, however only a limited number of metastases can be irradiated. We evaluated non-radiation based early CIBP relief options in NSCLC through a systematic review. Methods: Systematic review including all prospective articles published between 01-1994 and 06-2020 on Pubmed, Cochrane Library and ClinicalTrials.gov database. Inclusion: nonradiation based trials evaluating CIBP early pain relief options (initially defined as pain score evaluated within two weeks, because of no randomized trials, …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtymedicine.medical_treatmentPain reliefcancer induced bone painCochrane Librarylcsh:RC254-282DISEASEpain relieflaw.inventionPALLIATIVE RADIOTHERAPY03 medical and health sciences0302 clinical medicineRandomized controlled trialSDG 3 - Good Health and Well-beingbone metastasessystematic reviewlawQUALITY-OF-LIFEInternal medicinemedicineLung cancerBone painIBANDRONATEbisphosphonatesnon-small cell lung cancerDENOSUMABbusiness.industryGold standardCancermedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensEFFICACYRadiation therapy1ST-LINE TREATMENT030104 developmental biologyMETASTASESOncology030220 oncology & carcinogenesisZOLEDRONIC ACIDmedicine.symptombusinessFrontiers in Oncology
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Rho resonance, timelike pion form factor, and implications for lattice studies of the hadronic vacuum polarization

2020

We study isospin-1 P-wave ππ scattering in lattice QCD with two flavors of O(a) improved Wilson fermions. For pion masses ranging from mπ=265 MeV to mπ=437 MeV, we determine the energy spectrum in the center-of-mass frame and in three moving frames. We obtain the scattering phase shifts using Lüscher’s finite-volume quantization condition. Fitting the dependence of the phase shifts on the scattering momentum to a Breit-Wigner form allows us to determine the corresponding ρ mass mρ and gρππ coupling. By combining the scattering phase shifts with the decay matrix element of the vector current, we calculate the timelike pion form factor, Fπ, and compare the results to the Gounaris-Sakurai repr…

1 [isospin]Particle physicsdecay constant [rho(770)]High Energy Physics::Latticeclover [fermion]energy spectrumFOS: Physical sciencesWilson [quark]01 natural sciencesphase shiftHigh Energy Physics - LatticePionvector [correlation function]Charge radius0103 physical sciencesmagnetic moment [muon]quantum chromodynamicsmass [rho(770)]hadronic [vacuum polarization]ddc:530Vacuum polarizationflavor: 2 [quark]010306 general physicsnumerical calculationscharge radius [pi]PhysicsMuonAnomalous magnetic dipole moment010308 nuclear & particles physicsScatteringHigh Energy Physics - Lattice (hep-lat)scatteringlattice field theoryLattice QCDFermionBreit-Wignermass dependence [quark]form factor [pi]effect [finite size]vector [current]quantizationPhysical Review D
researchProduct

First measurement of the W-boson mass in run II of the Tevatron.

2007

7 pages, 4 figures.-- PACS nrs.: 14.70.Fm; 13.38.Be; 13.85.Qk.-- ISI Article Identifier: 000250140600014.-- ArXiv pre-print available at: http://arxiv.org/abs/0707.0085.-- et al.

13.38.Be 14.70.Fm 12.15.Ji 13.85.QkParticle physicsSingle measurementPhysics MultidisciplinaryTevatronFOS: Physical sciencesGeneral Physics and AstronomyElementary particleData recordingddc:500.201 natural sciencesParticle detectorHigh Energy Physics - ExperimentNuclear physicsHigh Energy Physics - Experiment (hep-ex)[PACS] Decays of W bosons0103 physical sciences[PHYS.HEXP]Physics [physics]/High Energy Physics - Experiment [hep-ex]W-boson massFermilabMeasurement theory010306 general physicsNuclear Experiment[PACS] Hadron-induced inclusive production with identified leptons photons or other nonhadronic particles (energy > 10 GeV)BosonsBosonPhysics010308 nuclear & particles physicsPhysicsHigh Energy Physics::PhenomenologyDetectorsTevatron[PACS] W bosonsHigh Energy Physics::ExperimentBar (unit)
researchProduct